GT-AS is currently being developed for the treatment of Angelman syndrome (AS).  AAV gene therapies can target brain regions of interest with targeted micro-dosing in AS by delivering the vector containing the transgene UBE3A that encodes for the ubiquitin protein ligase.  In pre-clinical studies, GT-AS has been shown to restore expression of protein and function. 

By selecting Confirm, you are leaving the PTC Therapeutics U.S. website. This external link is provided for your convenience. Please note that external links or web sites may not be controlled by PTC Therapeutics, and thus not subject to our Privacy policy and Terms of use.

Thank you for visiting our site.
Cancel Confirm
This site uses cookies to store information on your computer.
Cancel Continue